Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Paroxetine binding in aggressive schizophrenic patients.

I Modai1, A Gibel, B Rauchverger

  • 1Sha'ar Menashe Mental Health Center and Institute of Psychiatric Studies, Hadera, Israel. shrmodai@matat.health.gov.il

Psychiatry Research
|May 2, 2000
PubMed
Summary

Aggressive schizophrenic patients show higher [3H]paroxetine binding in blood platelets, indicating increased serotonin transporter activity. This suggests a link between current aggression and serotonin levels, not aggressive tendency.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychotropic and neurological medication effects on mitochondrial complex I and IV in rodent models.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2019
Same author

Multivariate meta-analyses of mitochondrial complex I and IV in major depressive disorder, bipolar disorder, schizophrenia, Alzheimer disease, and Parkinson disease.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2018
Same author

Abnormal neuronal differentiation and mitochondrial dysfunction in hair follicle-derived induced pluripotent stem cells of schizophrenia patients.

Molecular psychiatry·2013
Same author

Induced pluripotent stem cells from hair follicles as a cellular model for neurodevelopmental disorders.

Stem cell research·2011
Same author

Antidepressants and prolonged stress in rats modulate CAM-L1, laminin, and pCREB, implicated in neuronal plasticity.

Neurobiology of disease·2005
Same author

Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders.

Biochemical pharmacology·2004

Area of Science:

  • Neuroscience
  • Psychiatry
  • Biochemistry

Background:

  • Decreased central serotonergic activity is linked to aggression.
  • The relationship between serotonin activity and current aggression versus aggressive tendency is unclear.
  • Platelet [3H]paroxetine binding reflects peripheral serotonin transporter activity.

Purpose of the Study:

  • To investigate the association between platelet [3H]paroxetine binding and aggression in schizophrenic patients.
  • To differentiate between current aggression and aggressive history in relation to serotonin markers.
  • To explore the link between serotonin transporter activity and aggressive behavior in schizophrenia.

Main Methods:

  • Assayed [3H]paroxetine binding in blood platelets of schizophrenic patients (aggressive, non-aggressive with history, non-aggressive) and healthy volunteers.

Related Experiment Videos

  • Utilized clinical scales (PANSS, HAM-D, CGI) for patient evaluation.
  • Compared B(max) values of [3H]paroxetine binding across study groups.

    • Main Results:

    • Currently aggressive schizophrenic patients exhibited significantly higher B(max) of [3H]paroxetine binding compared to other groups.
    • No significant differences in binding were observed between non-aggressive patients (with or without history) and healthy volunteers.
    • No correlation was found between clinical rating scale scores and biochemical parameters.

    Conclusions:

    • An association exists between current aggression in schizophrenic patients and elevated B(max) values of [3H]paroxetine binding.
    • This finding suggests the association is related to the present state of aggression, not an underlying aggressive tendency.
    • Platelet serotonin transporter activity may serve as a biomarker for current aggressive states in schizophrenia.